Gapping down
In reaction to disappointing earnings/guidance:
- PIR -17.1%, UNFI -11.2%, MU -4.2%
Other news:
- MDXG -10.5% (determined previously announced separations of four senior executives will be treated as terminations 'for cause')
- TLRY -5.9% (ongoing volatility)
- WMC -5.3% (announces public offering of 6.5 mln shares of common stock)
- SGH -4.8% (files for $150 mln mixed securities shelf offering and files for approx 9.3 mln ordinary share offering by selling shareholders)
- FATE -4.5% (prices underwritten public offering of 9,259,260 shares of its common stock at a public offering price of $13.50 per share)
- CRSP -3.1% (prices underwritten public offering of 4,210,526 common shares at a public offering price of $47.50 per share)
- CRON -2.6% (ongoing volatility)
- SKY -2.1% (prices upsized underwritten public offering of 10 mln shares at a price to the public of $29.25 per share)
- SRPT -1.9% (announces that the EMA's CHMP has confirmed its May 31 negative opinion for a Conditional Marketing Application for eteplirsen)
- SJT -1.7% (Hilcorp revised 2018 capital expenditures plan; now estimates Q4 CapEx of $662k)
- CGC -1.5% (ongoing volatility)
- EVOP -1.3% (prices upsized underwritten offering of 7,022,225 shares of Class A common stock at a price to the public of $24.50 per share) .
Analyst comments:
- VNTR -2.2% (downgraded to Neutral from Overweight at JP Morgan)
- BZH -1.9% (downgraded to Neutral from Overweight at JP Morgan)
- JCI -1.7% (downgraded to Underweight from Neutral at JP Morgan)
- MTH -1.7% (downgraded to Neutral from Overweight at JP Morgan)
- PHM -1.4% (downgraded to Underweight from Overweight at JP Morgan)
- IAC -1% (downgraded to Neutral from Buy at Guggenheim)
- BLUE -1% (removed from Conviction Buy List at Goldman)
- ROP -0.8% (downgraded to Neutral from Overweight at JP Morgan)
- PAG -0.8% (downgraded to Neutral from Buy at Guggenheim)